Answers are grounded in this paper and cite their sources.
Introduction: To derive the reference intervals of serum soluble FMS like tyrosine kinase -1/Placental growth factor ratio in pregnant and non-pregnant females. Aims & Objectives: To derive the reference intervals of serum soluble FMS like tyrosine kinase -1/Placental growth factor ratio in pregnant and non-pregnant females. Place and Duration of Study: A comparative Cross-sectional study conducted in department of Chemical Pathology and Immunology, Chughtai Institute of Pathology, Lahore from February 2024 till May 2024 Material & Method: Blood samples from 120 pregnant and 120 non-pregnant females from 14±1 to 27±1 weeks were taken. All participants were of reproductive age group, disease free, non-hypertensive, non-diabetic, without any inherited or autoimmune disorders and not any significant drug history. Levels of placental growth factor (PGF) and soluble FMS like tyrosine kinase -1(sFlt-1) were estimated by Elecsys cobas e601. Data was analysed by SPSS 21. Shapiro-Wilk test and Kolmogorov Smirnov test were applied. p value <0.05 revealed that data findings were non- Gaussian. Reference intervals were calculated by rank-based method. Results: The reference intervals of serum sFlt-1/PGF ratio in non-pregnant females were 5.36 to 18.40 and in pregnant females 0.61 to 24.45 and they were determined on 2.5th and 97.5th centiles using 90% confidence interval. Conclusion: sFlt-1/PGF ratio can act as a predictive biomarker for cardiovascular disease in non-pregnant females and for pre-eclampsia in pregnant females. Current study findings would be helpful for healthcare providers to identify high- risk groups. The identification of low-risk groups results in a shorter duration of hospitalizations with potential economic benefits.
No takes yet. Share an insight, caveat, or question.
Rasheed et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: